"Monsanto’s (MON +2.8%) doing a lot of things right," OptionMonster’s Jon Najarian tells CNBC,...

"Monsanto’s (MON +2.8%) doing a lot of things right," OptionMonster’s Jon Najarian tells CNBC, adding the stock's two-year rise could continue as demand grows for MON’s genetically engineered, drought-resistant seeds. Shares are strong today, as investors focus on Goldman's upgrade rather than a study that said rats developed tumors after being exposed to certain MON products.

From other sites
Comments (3)
  • dacama1
    , contributor
    Comments (221) | Send Message
    Sorry about the rats but who cares?
    19 Sep 2012, 03:44 PM Reply Like
  • orsogrigio
    , contributor
    Comments (145) | Send Message
    well, dacama, monsanto, and ogm in general have very bad press since ever. I would like to have an answer to a very simple question : how many millions human beings would have died from starvation if ogm etc were not able to multiply output per acre of crops ? I like better human beings,and if rats signal a potential danger, let's find a solution out, but balancing, IMHO, costs and benefits. If the cost is a reduction of crop output, well, it's too high, i deem
    19 Sep 2012, 04:12 PM Reply Like
  • Cincinnatus
    , contributor
    Comments (5910) | Send Message
    If you click through the link they developed tumors because they were in contact with and probably regularly ingested Roundup weed killer. It's a French study by a "scientist" who is anti-GMO.


    I don't know why this is news. I could have predicted eating Roundup is likely to have negative effects.
    20 Sep 2012, 02:41 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs